Altimmune, Inc. (ALT)

7.36 +0.06 (+0.82%) 收市：04:00PM EDT

Altimmune, Inc.

910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240 654 1450
https://altimmune.com

版塊: Healthcare
行業: Biotechnology
全職員工: 59

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Vipin K. Garg Ph.D.	President, CEO & Director	986.14k	無	1958
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS	Chief Medical Officer	681.81k	無	1953
Mr. Raymond M. Jordt M.B.A.	Chief Business Officer	578.85k	無	1973
Mr. Richard I. Eisenstadt M.B.A.	Chief Financial Officer	619.69k	無	1958
Mr. Bertrand Georges Ph.D.	Chief Technology Officer	無	無	無
Dr. M. Scot Roberts Ph.D.	Chief Scientific Officer	599.25k	無	1959
Mr. Tony Blandin B.S.	Vice President of Quality & Compliance Management	無	無	無
Mr. Andrew Shutterly M.S.	Corporate Controller	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

公司管治

截至 2024年5月1日 止，Altimmune, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：4；股東權利：4；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。